Pancrelipase + Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency (EPI)
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Trial Timeline
Feb 25, 2020 → Mar 23, 2022
NCT ID
NCT03859869About Pancrelipase + Placebo
Pancrelipase + Placebo is a approved stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency (EPI). The current trial status is terminated. This product is registered under clinical trial identifier NCT03859869. Target conditions include Exocrine Pancreatic Insufficiency (EPI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03859869 | Approved | Terminated |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency (EPI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 33 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 77 |
| CREON | AbbVie | Approved | 85 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 52 |
| Pancrelipase Capsules | AbbVie | Approved | 85 |
| Lipacreon | Viatris | Pre-clinical | 20 |